Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.45 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.45 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | XBP1 | P17861 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2567016 | 0.91 | TSHR (0.52) | KMT2ATSHRMEN1CYP2C9CYP2C19 | |
| SCHEMBL3961573 | 0.86 | KMT2A (0.48) | KMT2ATSHRMEN1CYP2C9CYP2C19 | |
| SCHEMBL14912336 | 0.85 | TSHR (0.46) | KMT2ATSHRMEN1CYP2C9CYP2C19 | |
| SCHEMBL3477707 | 0.83 | CYP4F2 (0.47) | KMT2ATSHRMEN1CYP2C9CYP2C19 | |
| SCHEMBL2567248 | 0.83 | KMT2A (0.46) | KMT2ATSHRMEN1CYP2C9CYP2C19 | |
| SCHEMBL21866062 | 0.81 | KMT2A (0.44) | KMT2ATSHRMEN1CYP2C9CYP2C19 | |
| SCHEMBL2649492 | 0.81 | HSP90AA1 (0.46) | KMT2ATSHRMEN1CYP2C9CYP2C19 | |
| SCHEMBL7056273 | 0.80 | CYP2C9 (0.50) | TSHRCYP2C9CYP2C19CYP4F2CYP4A11 | |
| SCHEMBL5267090 | 0.80 | KDM4E (0.50) | KMT2ATSHRMEN1ALDH1A1HSD17B10 | |
| SCHEMBL9590155 | 0.79 | KMT2A (0.42) | KMT2ATSHRMEN1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | FLYNN DANIEL L | 2011-05-19 | — | — | US | disclosed |
| US-7897762-B2 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2011-03-01 | — | — | US | disclosed |
| EP-2063896-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Deciphera Pharmaceuticals, LLC. (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | DECIPHERA PHARMACEUTICALS, LLC (US) | 2009-04-16 | — | — | US | disclosed |
| WO-2008033999-A2 | KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118271-A1 | Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases | BRAF, PRKDC, RAF1 | KMT2A 1762/4885TSHR 283/4885MEN1 880/4885 |
| US-20090099190-A1 | Kinase inhibitors useful for the treatment of proliferative diseases | BRAF, PRKDC, RAF1 | KMT2A 1762/4885TSHR 283/4885MEN1 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.